Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease

Affiliations

• ¹ Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB, Canada.
• ² Department of Medicine, Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Calgary, Calgary, AB, Canada; Alberta Precision Laboratories, Public Health Laboratory, Calgary, AB, Canada.
• ³ Division of Infectious Diseases, University of Calgary, Calgary, AB, Canada; Alberta Precision Laboratories, Public Health Laboratory, Calgary, AB, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
• ⁴ Department of Clinical Neuroscience, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
• ⁵ IBD Clinical and Research Centre and Department of Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
• ⁶ Department of Microbiology, Immunology and Infectious Disease, University of Calgary, Calgary, AB, Canada.
• ⁷ Division of Rheumatology and Division of Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
• ⁸ ICES, Toronto, ON, Canada; SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON, Canada; Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
• ⁹ Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB, Canada. Electronic address: ggkaplan@ucalgary.ca.